PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AstraZeneca PLC (AZN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0463531089

CUSIP

046353108

Sector

Healthcare

IPO Date

May 12, 1993

Highlights

Market Cap

$205.69B

EPS (TTM)

$2.07

PE Ratio

32.00

PEG Ratio

0.71

Total Revenue (TTM)

$52.12B

Gross Profit (TTM)

$39.61B

EBITDA (TTM)

$16.91B

Year Range

$59.19 - $87.68

Target Price

$88.01

Short %

0.24%

Short Ratio

0.92

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
AZN vs. MRNA AZN vs. NVO AZN vs. CTLT AZN vs. CAH AZN vs. UNH AZN vs. VOO AZN vs. VTI AZN vs. NVS AZN vs. VONG AZN vs. FSPSX
Popular comparisons:
AZN vs. MRNA AZN vs. NVO AZN vs. CTLT AZN vs. CAH AZN vs. UNH AZN vs. VOO AZN vs. VTI AZN vs. NVS AZN vs. VONG AZN vs. FSPSX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AstraZeneca PLC, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-15.00%-10.00%-5.00%0.00%5.00%10.00%15.00%JulyAugustSeptemberOctoberNovemberDecember
-17.21%
7.29%
AZN (AstraZeneca PLC)
Benchmark (^GSPC)

Returns By Period

AstraZeneca PLC had a return of -1.95% year-to-date (YTD) and 0.21% in the last 12 months. Over the past 10 years, AstraZeneca PLC had an annualized return of 9.59%, while the S&P 500 had an annualized return of 11.01%, indicating that AstraZeneca PLC did not perform as well as the benchmark.


AZN

YTD

-1.95%

1M

1.97%

6M

-17.07%

1Y

0.21%

5Y*

7.68%

10Y*

9.59%

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of AZN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-1.05%-2.24%5.60%12.00%2.82%-0.04%1.49%11.38%-11.08%-8.68%-4.96%-1.95%
2023-3.58%1.16%6.49%5.49%-0.19%-2.07%0.18%-4.79%-0.15%-6.63%2.15%4.27%1.44%
2022-0.07%6.32%8.97%0.09%0.12%-0.62%0.24%-5.15%-12.09%7.24%15.58%-0.25%19.16%
20211.22%-2.54%2.77%6.74%6.97%5.51%-4.44%2.63%3.05%3.86%-12.10%6.24%19.73%
2020-2.33%-8.23%1.96%17.06%4.44%-3.13%5.46%1.20%-2.14%-8.47%5.54%-5.57%3.12%
2019-3.69%16.27%-2.77%-6.85%-0.74%10.43%5.16%4.81%-1.02%10.01%-1.12%2.85%35.68%
20181.04%-2.71%5.36%1.60%4.22%-5.18%11.45%-0.91%3.21%-2.00%2.68%-4.62%13.77%
2017-0.33%10.94%6.42%-2.86%13.69%-0.87%-11.47%0.32%13.58%1.83%-4.72%5.57%33.10%
2016-5.10%-8.20%-1.78%2.84%2.56%1.65%13.08%-2.64%0.15%-13.82%-7.70%4.51%-15.90%
20150.94%-0.32%-0.68%0.07%-1.36%-5.68%6.07%-6.22%1.73%0.22%6.77%-0.29%0.45%
20146.96%9.77%-4.25%21.84%-8.67%2.92%-2.05%5.80%-6.01%2.10%1.69%-5.11%23.55%
20131.93%-1.75%9.99%3.88%-1.29%-7.71%7.23%-1.25%5.53%1.79%8.19%3.81%33.17%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AZN is 42, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AZN is 4242
Overall Rank
The Sharpe Ratio Rank of AZN is 4545
Sharpe Ratio Rank
The Sortino Ratio Rank of AZN is 3636
Sortino Ratio Rank
The Omega Ratio Rank of AZN is 3737
Omega Ratio Rank
The Calmar Ratio Rank of AZN is 4646
Calmar Ratio Rank
The Martin Ratio Rank of AZN is 4545
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AstraZeneca PLC (AZN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for AZN, currently valued at 0.01, compared to the broader market-4.00-2.000.002.000.011.90
The chart of Sortino ratio for AZN, currently valued at 0.14, compared to the broader market-4.00-2.000.002.004.000.142.54
The chart of Omega ratio for AZN, currently valued at 1.02, compared to the broader market0.501.001.502.001.021.35
The chart of Calmar ratio for AZN, currently valued at 0.00, compared to the broader market0.002.004.006.000.002.81
The chart of Martin ratio for AZN, currently valued at 0.01, compared to the broader market0.0010.0020.000.0112.39
AZN
^GSPC

The current AstraZeneca PLC Sharpe ratio is 0.01. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of AstraZeneca PLC with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.000.501.001.502.002.503.003.50JulyAugustSeptemberOctoberNovemberDecember
0.01
1.90
AZN (AstraZeneca PLC)
Benchmark (^GSPC)

Dividends

Dividend History

AstraZeneca PLC provided a 2.30% dividend yield over the last twelve months, with an annual payout of $1.49 per share. The company has been increasing its dividends for 7 consecutive years.


2.00%2.50%3.00%3.50%4.00%4.50%5.00%5.50%$0.00$0.50$1.00$1.5020132014201520162017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM20232022202120202019201820172016201520142013
Dividend$1.49$1.45$1.45$1.40$1.40$1.40$1.37$1.37$1.37$1.38$1.40$1.40

Dividend yield

2.30%2.15%2.14%2.40%2.80%2.81%3.61%3.95%5.01%4.06%3.98%4.72%

Monthly Dividends

The table displays the monthly dividend distributions for AstraZeneca PLC. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.00$0.99$0.00$0.00$0.00$0.00$0.00$0.50$0.00$0.00$0.00$0.00$1.49
2023$0.00$0.99$0.00$0.00$0.00$0.00$0.00$0.47$0.00$0.00$0.00$0.00$1.45
2022$0.00$0.99$0.00$0.00$0.00$0.00$0.00$0.47$0.00$0.00$0.00$0.00$1.45
2021$0.00$0.95$0.00$0.00$0.00$0.00$0.00$0.45$0.00$0.00$0.00$0.00$1.40
2020$0.00$0.95$0.00$0.00$0.00$0.00$0.00$0.45$0.00$0.00$0.00$0.00$1.40
2019$0.00$0.95$0.00$0.00$0.00$0.00$0.00$0.45$0.00$0.00$0.00$0.00$1.40
2018$0.00$0.93$0.00$0.00$0.00$0.00$0.00$0.44$0.00$0.00$0.00$0.00$1.37
2017$0.00$0.93$0.00$0.00$0.00$0.00$0.00$0.44$0.00$0.00$0.00$0.00$1.37
2016$0.00$0.93$0.00$0.00$0.00$0.00$0.00$0.44$0.00$0.00$0.00$0.00$1.37
2015$0.00$0.94$0.00$0.00$0.00$0.00$0.00$0.44$0.00$0.00$0.00$0.00$1.38
2014$0.00$0.95$0.00$0.00$0.00$0.00$0.00$0.45$0.00$0.00$0.00$0.00$1.40
2013$0.95$0.00$0.00$0.00$0.00$0.00$0.45$0.00$0.00$0.00$0.00$1.40

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%2.3%
AstraZeneca PLC has a dividend yield of 2.30%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%46.3%
AstraZeneca PLC has a payout ratio of 46.30%, which is quite average when compared to the overall market. This suggests that AstraZeneca PLC strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-26.23%
-3.58%
AZN (AstraZeneca PLC)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AstraZeneca PLC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AstraZeneca PLC was 48.94%, occurring on Mar 9, 2009. Recovery took 977 trading sessions.

The current AstraZeneca PLC drawdown is 26.23%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-48.94%Oct 26, 2006594Mar 9, 2009977Jan 24, 20131571
-43.5%Mar 4, 2002127Aug 30, 2002382Mar 9, 2004509
-34.31%Apr 7, 1998476Feb 24, 200094Jul 10, 2000570
-31.26%Mar 10, 2004221Jan 24, 2005229Dec 19, 2005450
-29.82%May 2, 2014653Dec 1, 2016272Jan 2, 2018925

Volatility

Volatility Chart

The current AstraZeneca PLC volatility is 6.72%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%JulyAugustSeptemberOctoberNovemberDecember
6.72%
3.64%
AZN (AstraZeneca PLC)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AstraZeneca PLC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of AstraZeneca PLC compared to its peers in the Drug Manufacturers - General industry.


PE Ratio
200.0400.0600.0800.01,000.032.0
The chart displays the price to earnings (P/E) ratio for AZN in comparison to other companies of the Drug Manufacturers - General industry. Currently, AZN has a PE value of 32.0. This PE ratio falls in the average range for the industry.
PEG Ratio
10.020.030.00.7
The chart displays the price to earnings to growth (PEG) ratio for AZN in comparison to other companies of the Drug Manufacturers - General industry. Currently, AZN has a PEG value of 0.7. This PEG ratio falls in the average range for the industry.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for AstraZeneca PLC.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab